TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26913398

Group type: EXPERIMENTAL
Intervention: HyperCVAD
Number of subjects: 97

Group type: COMPARATOR
Intervention: CHOP/CHOP-like
Number of subjects: 97
Study: 23761178

Group type: EXPERIMENTAL
Intervention: Limb preconditioning before induction of ischemia for surgery (tourniquet inflation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no limb preconditioning)
Number of subjects: 60
Study: 22609217

Group type: EXPERIMENTAL
Intervention: Pilates exercises for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no Pilates exercises)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 31
Study: 20737165

Group type: EXPERIMENTAL
Intervention: Caffeine (240 mg) via chewing gum
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 18831749

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (alcohol extract) administered for 10 days at the first sign of each common cold
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) including cranial manipulation, with up to five visits over 3 months
Number of subjects: 90
Study: 16149206

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11841372

Group type: EXPERIMENTAL
Intervention: 3.0% diclofenac in 2.5% hyaluronan gel for 60 days
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 3.0% diclofenac in 2.5% hyaluronan gel for 30 days
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo (2.5% hyaluronan gel) for 60 days
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo (2.5% hyaluronan gel) for 30 days
Number of subjects: 195
Study: 10080462

Group type: EXPERIMENTAL
Intervention: Sibrafiban (oral, selective antagonist of platelet glycoprotein IIb/IIIa receptor)
Number of subjects: 90
Study: 7672773

Group type: EXPERIMENTAL
Intervention: Aluminium phosphate gel (11 g five times a day)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Ranitidine (300 mg once daily for 6 weeks)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Aluminium phosphate gel
Number of subjects: 304

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 304
Study: 1596776

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3966685

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study: 30898502

Group type: EXPERIMENTAL
Intervention: Prophylactic incisional negative pressure wound therapy (iNPWT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard postoperative wound care
Number of subjects: 55
Study: 30096637

Group type: EXPERIMENTAL
Intervention: e‐SBI (10 min of assessment and personalized feedback)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Screening alone (control)
Number of subjects: 837
Study: 27572272

Group type: EXPERIMENTAL
Intervention: Internet-based information and skill-building program for family carers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 24942912

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 18201

Group type: COMPARATOR
Intervention: D-dimer level
Number of subjects: 18201
Study: 24167223

Group type: COMPARATOR
Intervention: SUR group (n = 14)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SUR+EX group (n = 12)
Number of subjects: 26
Study: 21367355

Group type: EXPERIMENTAL
Intervention: Lamotrigine (titrated to a maximum of 400 mg/d for 10 weeks)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Lamotrigine (in completer analysis)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo (in completer analysis)
Number of subjects: 183
Study: 19349934

Group type: EXPERIMENTAL
Intervention: Foam dressing (Suprasorb P)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Collagen dressing (Suprasorb C) plus foam dressing
Number of subjects: 3

Group type: COMPARATOR
Intervention: Paraffin gauze (control)
Number of subjects: 3
Study: 18604018

Group type: EXPERIMENTAL
Intervention: Fungal maxillary sinusitis diagnosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Identification of fungal species
Number of subjects: 100
Study: 15156253

Group type: EXPERIMENTAL
Intervention: Aescin and essential phospholipids (AEPL) gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11839116

Group type: COMPARATOR
Intervention: 1 standard information session
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 4 individual coping skills training sessions (once a month)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 12 group sessions (twice a month)
Number of subjects: 39
Study: 9736666

Group type: EXPERIMENTAL
Intervention: Ethanol (10-25 mM, 0.05-0.125 gm/dl)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7593457

Group type: EXPERIMENTAL
Intervention: Continuous transdermal estradiol (50 ug/24 hrs) with periodic medroxyprogesterone (10.0 mg/day) (n = 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Continuous oral estradiol (2.0 mg/day) and continuous norethisterone acetate (1.0 mg/day) (n = 13)
Number of subjects: 26
Study: 2282112

Group type: EXPERIMENTAL
Intervention: Directing style of consultation
Number of subjects: 359

Group type: COMPARATOR
Intervention: Sharing style of consultation
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Longer consultations (both styles)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Advice consultations
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Psychological problems
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Chronic problems
Number of subjects: 359
Study: 7305698

Group type: EXPERIMENTAL
Intervention: Operant conditioning of the EEG (feedback training)
Number of subjects: 8

Group type: COMPARATOR
Intervention: False (noncontingent) feedback
Number of subjects: 8
Study: 31455474

Group type: EXPERIMENTAL
Intervention: Onlay mesh repair (Group 1)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sublay mesh fixation technique (Group 2)
Number of subjects: 65
Study: 28388994

Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin <12 g/dl in women or <13 g/dl in men (anemia)
Number of subjects: 16318
Study: 25879863

Group type: EXPERIMENTAL
Intervention: Sertraline (75 mg/day) plus deanxit (one piece/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sertraline (75 mg/day) plus placebo (one piece/day)
Number of subjects: 75
Study: 23866780

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Lidocaine and placebo
Number of subjects: 126

Group type: COMPARATOR
Intervention: Lidocaine and methylprednisolone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Bupivacaine and placebo
Number of subjects: 126
Study: 21463215

Group type: EXPERIMENTAL
Intervention: Oral glutamine (0.3 g/kg/day, n = 51-Gln group)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (caloreen-isocaloric, n = 50-control group)
Number of subjects: 101
Study: 19640325

Group type: EXPERIMENTAL
Intervention: BHBH intervention (personalised lifestyle advice, goal-setting, social support)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison group (CG)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: BHBH intervention
Number of subjects: 62
Study: 17371337

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg/day)
Number of subjects: 96
Study: 15038804

Group type: EXPERIMENTAL
Intervention: Medication Alliance training program
Number of subjects: 23
Study: 11179160

Group type: EXPERIMENTAL
Intervention: Radiography of the lumbar spine
Number of subjects: 421
Study: 9662766

Group type: EXPERIMENTAL
Intervention: Provider referral approach to partner notification
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: Cost of intervention
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Effectiveness comparison
Number of subjects: 1070
Study: 7840516

Group type: EXPERIMENTAL
Intervention: High dose methotrexate followed by 5‐Fluorouracil and leucovorin rescue on day 1 (Arm A)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Folinic acid and 5‐Fluorouracil on day 1 to 5 (Arm B)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (non-responders of group B)
Number of subjects: 104
Study: 2205947

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7352844

Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued hospitalization
Number of subjects: 0
Study: 31964367

Group type: EXPERIMENTAL
Intervention: Modified OIDP scale
Number of subjects: 220
Study: 30262878

Group type: EXPERIMENTAL
Intervention: Work and SCI resource (n=25)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait-list control group (n=23)
Number of subjects: 48
Study: 28633001

Group type: EXPERIMENTAL
Intervention: SIT (Wingate‐based sprint interval training)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HIIT (high‐intensity interval training)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SIT and HIIT
Number of subjects: 30
Study: 26436208

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 1385

Group type: COMPARATOR
Intervention: Sham intervention (sham-RIPC)
Number of subjects: 1385
Study: 24961091

Group type: COMPARATOR
Intervention: 0.5% betaxolol
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0.2% brimonidine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combined administration of 0.5% betaxolol and 0.2% brimonidine
Number of subjects: 54
Study: 21421493

Group type: EXPERIMENTAL
Intervention: G‐CSF (600 µg/day) for 7 consecutive days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional treatment (medication and interventional therapy)
Number of subjects: 38
Study: 19266831

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.8 mg.kg(‐1) at 1 mg.ml(‐1) (0.8 ml.kg(‐1)) in G1 group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.8 mg.kg(‐1) at 2 mg.ml(‐1) (0.4 ml.kg(‐1)) in G2 group
Number of subjects: 72
Study: 17885570

Group type: EXPERIMENTAL
Intervention: PASCET‐PI (n = 22)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n = 19)
Number of subjects: 41
Study: 15466095

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 337

Group type: COMPARATOR
Intervention: E-mail follow-up
Number of subjects: 337
Study: 11719029

Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control vaccinia virus (V) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation arms from other studies (ECOG, Mayo, WHO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ECOG and Mayo treatment arms
Number of subjects: 0
Study: 9593234

Group type: EXPERIMENTAL
Intervention: Preoperative high-dose radiotherapy (5 x 5 Gy)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 171
Study: 7874153

Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte solution (C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal and water (M)
Number of subjects: 10
Study: 3606231

Group type: EXPERIMENTAL
Intervention: BSHGH (0.1 mg/kg/24 h)
Number of subjects: 14
Study: 29329923

Group type: EXPERIMENTAL
Intervention: 20% protein diet
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 27% protein diet
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 35% protein diet
Number of subjects: 76
Study: 27031181

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily for 28 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 100
Study: 25742308

Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Pressure Assist/Control Ventilation
Number of subjects: 229
Study: 23178468

Group type: EXPERIMENTAL
Intervention: Somatostatin administration (infused 1 day before operation and continued for 7 days after surgery)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Somatostatin administration
Number of subjects: 67
Study: 21436689

Group type: EXPERIMENTAL
Intervention: lotrafilcon B/polyhexamethylene biguanide (PHMB)‐based multipurpose (MPS) solution (MPS‐1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: lotrafilcon B/polyquaternium‐1 and myristamidopropyl dimethylamine‐based solution (MPS‐2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: lotrafilcon B and another PHMB‐based solution (MPS‐3)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 25
Study: 18227529

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 2006

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2006
Study: 16540554

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 549
Study: 12941723

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg once daily for 16 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 10960381

Group type: EXPERIMENTAL
Intervention: Morphine (administered via retrobulbar catheter)
Number of subjects: 0
Study: 8977350

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.4, 0.8, and 1 mg bolus injections followed by 1 mg/h infusion for three hours)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (three sequential bolus injections followed by placebo infusion)
Number of subjects: 49
Study: 1475616

Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: H. pylori-positive subjects
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: H. pylori-negative subjects
Number of subjects: 15
Study: 6202898

Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) with preoperative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tegafur (FT) with preoperative radiotherapy
Number of subjects: 0
Study: 31097163

Group type: COMPARATOR
Intervention: MVS alone
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: MVS + PVI
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: MVS + biatrial maze
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: PPM implantation
Number of subjects: 243
Study: 29530020

Group type: EXPERIMENTAL
Intervention: Fatty fish (herring/mackerel)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Meat (chicken/lamb/beef)
Number of subjects: 232
Study: 27473050

Group type: EXPERIMENTAL
Intervention: Low tidal-volume ventilation (6 mL•kg(‐1) ideal body weight) with PEEP of 3 cm H2O
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional tidal-volume ventilation (12 mL•kg(‐1) ideal body weight) with PEEP of 3 cm H2O
Number of subjects: 25
Study: 24680265

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration and intracoronary tirofiban combined with nitroprusside bolus (200 µg prior to the first balloon inflation, Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration and intracoronary tirofiban bolus (25 µg/kg prior to the first balloon inflation, Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thrombus aspiration alone (Group A)
Number of subjects: 90
Study: 23124502

Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) involvement in educational intervention
Number of subjects: 0
Study: 19144653

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy (Angiotensin-converting enzyme inhibitors + Angiotensin receptor blockers)
Number of subjects: 0
Study: 17256447

Group type: EXPERIMENTAL
Intervention: Psychotropic drugs (antidepressants and/or benzodiazepines)
Number of subjects: 1756

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 1756

Group type: EXPERIMENTAL
Intervention: Counseling or advice from GP
Number of subjects: 1756
Study: 15992236

Group type: EXPERIMENTAL
Intervention: Static magnets
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Static magnets (in better quality studies)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Static magnets (after excluding inadequate treatment studies)
Number of subjects: 21
Study: 12162471

Group type: EXPERIMENTAL
Intervention: GW433908G tablet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GW433908G suspension
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GW433908G tablets
Number of subjects: 40

Group type: COMPARATOR
Intervention: amprenavir capsules
Number of subjects: 40
Study: 9475647

Group type: EXPERIMENTAL
Intervention: Phosphagen HP with 15.75 g x d(‐1) of HPCE pure creatine monohydrate (HP)
Number of subjects: 25
Study: 8751030

Group type: EXPERIMENTAL
Intervention: Homeopathic after-bite gel
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 68

Group type: COMPARATOR
Intervention: Untreated spots
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Homeopathic after-bite gel vs Untreated spots
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Homeopathic after-bite gel vs Placebo gel
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Homeopathic after-bite gel vs No treatment (pooled data)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Homeopathic after-bite gel vs Placebo gel (pooled data)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Extent of itching after treatments
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Extent of itching correlation with erythema
Number of subjects: 68
Study: 2210982

Group type: EXPERIMENTAL
Intervention: Povidone-iodine enema alone (Group A, n = 18)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Parenteral piperacillin alone (Group B, n = 22)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Piperacillin in combination with povidone-iodine enema (Group C, n = 25)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (Group D, n = 16)
Number of subjects: 81
Study: 345198

Group type: EXPERIMENTAL
Intervention: 1000 mg aspirin (ASA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Initial pain sensitivity
Number of subjects: 32
Study: 31116274

Group type: EXPERIMENTAL
Intervention: Pleural drain in the left lateral intercostal region
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pleural drain in the subxiphoid position
Number of subjects: 48
Study: 27809707

Group type: EXPERIMENTAL
Intervention: Educational program (four-month duration, including two face-to-face sessions and two follow-up calls)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 100
Study: 25730053

Group type: EXPERIMENTAL
Intervention: 50 U/mL BTX‐A injection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 25 U/mL BTX‐A injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (50 U/mL and 25 U/mL BTX‐A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-concentration group (50 U/mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-concentration group (25 U/mL)
Number of subjects: 20
Study: 24095604

Group type: EXPERIMENTAL
Intervention: Educational intervention regarding anxiety and satisfaction (oral and written information on safety, risks, and benefits of haemotherapy)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (equivalent information on general health topics)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 21683209

Group type: EXPERIMENTAL
Intervention: Immediate laparoscopic surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interval appendectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (nonoperative initial management)
Number of subjects: 40
Study: 19699838

Group type: EXPERIMENTAL
Intervention: 113 g serving of 90% lean beef (30 g protein)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 340 g serving of 90% lean beef (90 g protein)
Number of subjects: 34
Study: 17723973

Group type: EXPERIMENTAL
Intervention: Acupressure to P6 point
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo acupressure to SI3 point
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 160
Study: 15066073

Group type: EXPERIMENTAL
Intervention: Wobble-board training for 5 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal activity only (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Wobble-board training and normal activity (both conditions tested)
Number of subjects: 20
Study: 11211888

Group type: EXPERIMENTAL
Intervention: Bio‐Hep‐B
Number of subjects: 36

Group type: COMPARATOR
Intervention: Engerix‐B
Number of subjects: 36
Study: 9510452

Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Intra‐erythrocyte free iron concentration
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Hypoxanthine levels
Number of subjects: 164
Study: 8063021

Group type: EXPERIMENTAL
Intervention: 400 mg acyclovir twice daily (first year)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Open-label acyclovir suppressive therapy (after first year)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Suppressive therapy for 5 years
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 1100
Study: 2660991

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 266

Group type: COMPARATOR
Intervention: Aspirin with dipyridamole
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266